Hodgkin's disease. Treatment of resistant patients

M. De Lena, A. Santoro

Research output: Contribution to journalArticlepeer-review


This paper summarizes the preliminary results obtained at the Istituto Nazionale Tumori of Milan with a new multiple-agent chemotherapy (ABVD) specifically designed in 1973 to serve as an alternative treatment for MOPP failures. Thirty patients were suitable for the evaluation of response after secondary treatment. Twenty-one patients were previously treated with MOPP and nine with ABVD. Although based on a limited series, the findings indicate that ABVD is effective in producing significant response in about two-thirds of patients resistant to primary MOPP chemotherapy. Since secondary MOPP treatment induced objective response, though of limited magnitude and duration in ABVD failures, we can conclude that no cross-resistance exists between the two combinations. This is also supported by markedly improved median survival observed in patients achieving complete remission.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalCancer Clinical Trials
Issue number1
Publication statusPublished - 1979

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hodgkin's disease. Treatment of resistant patients'. Together they form a unique fingerprint.

Cite this